|
KMID : 4412620170230010013
|
|
Clinical Hypertension
2017 Volume.23 No. 1 p.13 ~ p.13
|
|
|
Pathophysiology of copeptin in kidney disease and hypertension
|
|
Afsar Baris
|
|
|
Abstract
|
|
|
|
Copeptin is derived from the cleavage of the precursor of arginine vasopressin (AVP), produced in an equimolar ratio in hypothalamus and processed during axonal transport AVP is an unstable peptide and has a short half-life of 5?20 min. Unlike AVP, copeptin is a stable molecule and can easily be measured. Recent evidence suggest that increased copeptin levels have been associated with worse outcomes in various clinical conditions including chronic kidney disease (CKD) and hypertension. In this review, the data regarding copeptin with kidney function (evaluated as glomerular filtration rate, increased albumin/protein excretion or both) and hypertension with regard to performed studies, prognosis and pathogenesis was summarised.
|
|
|
KEYWORD
|
|
|
Albuminuria, Copeptin, Kidney damage, Chronic kidney disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|